ACE inhibitory peptide TLRFAHGME derivatives and their applications

By acetylation or myristylation of the ACE inhibitory peptide TLRFALHGME, its binding force with ACE is enhanced, solving the problems of insignificant blood pressure lowering effect and toxic side effects in the existing technology, and achieving a more efficient blood pressure lowering effect.

CN117003821BActive Publication Date: 2026-05-26FISHERIES RESEARCH INSTITURE OF FUJIAN
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
FISHERIES RESEARCH INSTITURE OF FUJIAN
Filing Date
2023-08-03
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

The existing ACE inhibitory peptide TLRFALHGME has not shown significant blood pressure lowering effects, and conventional antihypertensive drugs have toxic side effects.

Method used

By acetylation or myristylation of the ACE inhibitory peptide TLRFALHGME, ACE inhibitory peptide derivatives are formed, which enhance its hydrogen bond, hydrophobic bond and van der Waals force interactions with ACE and increase its binding free energy with ACE.

Benefits of technology

It significantly enhanced the antihypertensive effect of the ACE inhibitory peptide TLRFALHGME derivative, with the maximum antihypertensive value increasing by 160.7% and 125.7%, respectively, and reduced toxic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117003821B_ABST
    Figure CN117003821B_ABST
Patent Text Reader

Abstract

This invention discloses ACE inhibitory peptide TLRFALHGME derivatives and their applications, belonging to the field of peptide derivative technology. The structural formulas are shown in Formula 1 or Formula 2: Formula 1, Formula 2. The ACE inhibitory peptide TLRFALHGME derivatives and their applications of this invention significantly enhance the antihypertensive effect of acetylated and myristylated derivatives of ACE inhibitory peptide TLRFALHGME, with maximum antihypertensive values ​​increased by 160.7% and 125.7% respectively compared to ACE inhibitory peptide TLRFALHGME.
Need to check novelty before this filing date? Find Prior Art